1-3 of 3
pharmacodynamics
Close
Sort by
Journal Articles

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Clinical Trials & Observations
Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, Jacek Treliński, Nichola Cooper, Peter Kiessling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, James B. Bussel, Stephen Jolles
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4136–4146.
https://doi.org/10.1182/bloodadvances.2020002003
Published: 2020
Includes: Supplemental data
Journal Articles

FVIII half-life extension by coadministration of a D′D3 albumin fusion protein in mice, rabbits, rats, and monkeys

Sabine Pestel, Hans-Wilhelm Beltz, Philipp Claar, Holger Lind, Marcel Mischnik, Elmar Raquet, Arna Andrews, Jason Simmonds, Vesna Tomasetig, Steven K. Dower, Anna Tjärnlund-Wolf, Stefan Schulte, Peter M. Schmidt, Thomas Weimer
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1870–1880.
https://doi.org/10.1182/bloodadvances.2019000999
Published: 2020
Includes: Supplemental data
Journal Articles

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Clinical Trials & Observations
Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani
Journal: Blood Advances
Blood Adv (2017) 1 (15): 1167–1180.
https://doi.org/10.1182/bloodadvances.2016001925
Published: 2017
Includes: Supplemental data